| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/28/2010 | CA2730264A1 Ophthalmic device having therapeutic agent delivery capability and method of forming same |
| 01/28/2010 | CA2728357A1 Device and method for controlling insects |
| 01/28/2010 | CA2724533A1 Stabilized atypical antipsychotic formulation |
| 01/27/2010 | EP2147683A1 Construct and method for the internalization of cargo molecules into a cell |
| 01/27/2010 | EP2147679A2 Compositions and methods for modulating blood-brain barrier transport |
| 01/27/2010 | EP2147670A1 Chemically stable compositions of 4-hydroxy tamoxifen |
| 01/27/2010 | EP2147042A1 Dendritic molecules |
| 01/27/2010 | EP2146750A1 Stabilized suspension |
| 01/27/2010 | EP2146748A1 Macrophage transfection method |
| 01/27/2010 | EP2146747A1 Novel strategies for delivery of active agents using micelles and particles |
| 01/27/2010 | EP2146727A1 High viscosity macromolecular compositions for treating ocular conditions |
| 01/27/2010 | EP2146694A1 Formulation of active agent loaded activated plga nanoparticles for targeted cancer nano-therapeutics |
| 01/27/2010 | EP2146632A1 Compositions and methods for cellular imaging and therapy |
| 01/27/2010 | EP2146588A1 Method for the production of a food, a food supplement, or consumable good |
| 01/27/2010 | EP1489125B1 Compound of hydrophilic polymer-polycarboxyl oligopeptide and medicines, medical composite comprising above compound and use of above compound in medicines |
| 01/27/2010 | CN101636182A Novel psychotropic agents having glutamate NMDA activity |
| 01/27/2010 | CN101636181A Novel injectable chitosan mixtures forming hydrogels |
| 01/27/2010 | CN101633692A Methods for making apo-2 ligand using divalent metal ions |
| 01/27/2010 | CN101632835A Disintegration method of concentrated pills |
| 01/27/2010 | CN101632834A Magnetic nano-carrier with targeted hydrophobic drug delivery to tumor and preparation method thereof |
| 01/27/2010 | CN101632642A Formulations for oral administration of active compounds |
| 01/27/2010 | CN101632627A Solution for ungual and peri-ungual application |
| 01/27/2010 | CN100584857C Process of high purity albumin production |
| 01/27/2010 | CN100584389C Hollow ball shaped nanometer hydroxylapatite material and the preparing method |
| 01/27/2010 | CN100584386C Nano microgel, and its preparing method and use |
| 01/27/2010 | CN100584385C Tablet and process for producing the same |
| 01/27/2010 | CN100584384C Method of obtaining oil solution of water-soluble medication and obtained preparation in oil phase |
| 01/27/2010 | CN100584383C Pharmaceutical composition with Meclofenoxate hydrochloride capable of preventing hydrolysis |
| 01/27/2010 | CN100584365C Pharmaceutical composition for treating acne |
| 01/27/2010 | CN100584353C A medicinal composition for treating oral ulcer and its preparation method |
| 01/27/2010 | CN100584341C Method for masking stench of animal traditional Chinese medicinal formulation granule |
| 01/27/2010 | CN100584334C Stabled desogestrel medical combination and the preparing method |
| 01/27/2010 | CN100584330C Substituted benzimidazole proton pump inhibitor composition, and its preparing method |
| 01/27/2010 | CN100584329C Anethol trithione soft capsule and preparation method thereof |
| 01/27/2010 | CN100584322C Compositions comprising modafinil compounds |
| 01/27/2010 | CN100584314C Composition having gelling properties for the prolonged delivery of bioactive substances |
| 01/26/2010 | US7652071 Penetration of active substances into cells and organs |
| 01/26/2010 | US7652030 Acidic aqueous solution containing ipratropium and xylometazoline |
| 01/26/2010 | US7651996 1 wt.% insulin, 2 wt. % oxacyclohexadecane-2-one as permeation enhancer, 1% wt. cottenseed oil, 0.6 wt.% Sorbitan, 0.7 wt. % Polysorbate 20, 94.3 wt. % water, buffer amounts of 0.3 wt. % citric acid (monohydrate) and 0.1 wt. % sodium citrate (dihydrate); nasal drug delivery |
| 01/26/2010 | US7651995 Absorption enhancers such as e.g. BHT, BHA or propyl gallate |
| 01/26/2010 | US7651974 Adsorbent for oral administration |
| 01/26/2010 | US7651706 Especially animal or vegetable extracts, containing one or more saccharides such as sugar alcohols to prevent precipitation and effect storage stability over a long period of time; pH is adjusted to 4.5-5.5 |
| 01/26/2010 | US7651703 Comprising hyaluronic acid or sodium hyaluronate dissolved in physiological buffer at concentration of 0.01-3 percent weight per volume and particles comprising first component biologically active agent and second component biocompatible polymeric matrix; use of 23-gauge or smaller bore needle |
| 01/26/2010 | US7651702 Crosslinking hyaluronan and chitosanic polymers |
| 01/26/2010 | US7651700 Topical diclofenac patch |
| 01/26/2010 | US7651698 Prolonged release bioadhesive therapeutic systems |
| 01/26/2010 | US7651697 Nitric oxide-producing hydrogel materials |
| 01/26/2010 | US7651681 Method and compositions for in situ formation of protective and/or medicated films on body tissue |
| 01/26/2010 | CA2471651C Amorphous substance of tricyclic triazolobenzazepine derivative |
| 01/26/2010 | CA2465206C Polymeric thiol-linked prodrugs |
| 01/26/2010 | CA2447099C Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/26/2010 | CA2426852C Formulation containing phosphate derivatives of electron transfer agents |
| 01/26/2010 | CA2421588C Tnf receptor-like molecules and uses thereof |
| 01/26/2010 | CA2390029C Suspension comprising oxcarbazepine |
| 01/26/2010 | CA2388344C Amphiphilic polymeric vesicles |
| 01/26/2010 | CA2385974C Treating endometriosis or infertility or improving fertility |
| 01/26/2010 | CA2383250C Phytochemicals for treatment of mastalgia and endometriosis |
| 01/26/2010 | CA2383105C Intranasal influenza virus vaccine |
| 01/26/2010 | CA2383027C Apparatus and method for anesthetizing the cervical region of a female |
| 01/26/2010 | CA2272582C Process for preparing polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents |
| 01/26/2010 | CA2204666C Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| 01/26/2010 | CA2185347C A carrier for hydrophobic drugs and a pharmaceutical composition based thereon |
| 01/26/2010 | CA2162305C Method of increasing viability of stored erythrocytes by addition of lipoic, dihydrolipoic, 6,8-bisnortetralipoic or tetranorlipoic acid |
| 01/21/2010 | WO2010009449A2 Extended release pharmaceutical formulations of s-adenosylmethionine |
| 01/21/2010 | WO2010009124A2 Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| 01/21/2010 | WO2010009122A1 Medical devices and methods for delivery of nucleic acids |
| 01/21/2010 | WO2010009065A2 Amphipathic peptide compositions |
| 01/21/2010 | WO2010009034A2 Method for treating atrophic age related macular degeneration |
| 01/21/2010 | WO2010008601A1 Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic |
| 01/21/2010 | WO2010008600A1 Topical drug delivery system |
| 01/21/2010 | WO2010008582A2 Phagocytic cell drug delivery system |
| 01/21/2010 | WO2010008135A1 Oral soft capsule of aceclofenac having improved stability |
| 01/21/2010 | WO2010007604A2 Inhalable microparticles, and methods for the production thereof |
| 01/21/2010 | WO2010007252A2 Formulation for improving the bioavailability of a hydrophobic molecule |
| 01/21/2010 | WO2010007016A1 Method for manufacturing medicinal compounds containing dabigatran |
| 01/21/2010 | WO2010006708A1 Silica sol material having at least one therapeutically active substance for producing biologically degradable and/or resorbable silica gel materials for human medicine and/or medical technology |
| 01/21/2010 | WO2010006454A2 Functionalized polypeptides |
| 01/21/2010 | WO2010006451A1 Dosage form containing a statin |
| 01/21/2010 | WO2010006442A1 Articles of manufacture releasing an active ingredient |
| 01/21/2010 | WO2009146153A3 Manufacture, transport and delivery of material containing highly polarized nuclei |
| 01/21/2010 | WO2009146147A3 Target-responsive hydrogels |
| 01/21/2010 | WO2009144481A3 Peptide conjugates for delivery of biologically active compounds |
| 01/21/2010 | WO2009142852A3 Process for manufacturing flowable powder drug compositions |
| 01/21/2010 | WO2009139905A3 Conjugates of a cholinesterase moiety and a polymer |
| 01/21/2010 | WO2009134092A3 Poorly soluble drug-containing release-controlled polymeric nanoparticle formulation |
| 01/21/2010 | WO2009134079A3 Pharmaceutical formulation |
| 01/21/2010 | WO2009134056A3 Pharmaceutical formulation |
| 01/21/2010 | WO2009129433A3 Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
| 01/21/2010 | WO2009120885A3 Stabilizing lipid compositions for oral pharmaceutical agents |
| 01/21/2010 | WO2009117127A3 Nerve repair with a hydrogel and optional adhesive |
| 01/21/2010 | WO2009103741A3 Use of fsh receptor ligands for diagnosis and therapy of cancer |
| 01/21/2010 | WO2009026315A3 Use of carbon nanotube for drug delivery |
| 01/21/2010 | US20100017898 Therapeutic applications of noncovalent dimerizing antibodies |
| 01/21/2010 | US20100016790 Treatment And Pre-Treatment Device, And Manufacturing Method Therefor, Involving Nitric Oxide |
| 01/21/2010 | US20100016562 Reducing the immunogenicity of fusion proteins |
| 01/21/2010 | US20100016549 Peyer's patch and/or m-cell targeting ligands |
| 01/21/2010 | US20100016545 Process for the covalent coupling of two molecules by means of a diels-alder reaction with inverse electron requirement |
| 01/21/2010 | US20100016451 Orally Disintegrative Dosage Form |
| 01/21/2010 | US20100016450 Controlled release delivery devices for the treatment of otic disorders |
| 01/21/2010 | US20100016449 Formulations with Improved Bioavailability |